Acquired resistance to PD-L1 inhibition can rewire the interferon-regulated secretory machinery in tumor cells, altering the ...

Researchers at the Icahn School of Medicine at Mount Sinai have identified the mechanism of action of a treatment for ...

There is growing evidence that immune-positron emission tomography (immuno-PET) can provide a real-time quantitative readout ...

Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...

Agilent Technologies Inc. (NYSE: A) today announced the issuing of a Class C companion diagnostic In Vitro Diagnostic ...

BNT327, now in early-phase trials, is part of a class of drugs that could one day challenge Keytruda’s dominance. BioNTech ...

See how Checkpoint Therapeutics, Inc.'s FDA-approved Unloxcyt drug for cSCC is set to disrupt the market with innovative ...

A multi-institutional clinical trial led by the University of Navarra, Spain, found that blocking growth differentiation ...

Another checkpoint inhibitor has entered the fray, as Checkpoint Therapeutics has passed the FDA’s checkpoint with its PD-L1 inhibitor cosibelimab. The FDA has approved cosibelimab under the brand ...

Updated results from the CheckMate 274 trial support the use of adjuvant nivolumab as standard care for high-risk muscle-invasive urothelial carcinoma, according to researchers.

New data suggests researchers may have found one of their most promising candidates yet for the next generation in ...

Wellington Management Group LLP lifted its stake in Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) by 16.2% during the third quarter, according to its most recent disclosure with the Securities ...